$7.85
3.62% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US00654J1079
Symbol
ADXN

Addex Therapeutics Ltd - ADR Stock price

$7.85
-0.98 11.07% 1M
+1.12 16.66% 6M
+0.85 12.18% YTD
-0.20 2.45% 1Y
-17.95 69.56% 3Y
-280.80 97.28% 5Y
-282.15 97.29% 10Y
-282.15 97.29% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.30 3.62%
ISIN
US00654J1079
Symbol
ADXN
Industry

Key metrics

Basic
Market capitalization
$12.8m
Enterprise Value
$9.4m
Net debt
positive
Cash
$3.5m
Shares outstanding
98.4m
Valuation (TTM | estimate)
P/E
71.4 | negative
P/S
16.2 | 13.6
EV/Sales
11.9 | 9.9
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
90.6%
Return on Equity
72.9%
ROCE
-25.8%
ROIC
-34.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$790.0k | $942.0k
EBITDA
$-2.4m | $-4.2m
EBIT
$-2.7m | $-4.2m
Net Income
$11.2m | $-7.4m
Free Cash Flow
$-4.3m
Growth (TTM | estimate)
Revenue
-53.5% | 88.4%
EBITDA
76.7% | -23.4%
EBIT
74.9% | -24.9%
Net Income
180.6% | -185.3%
Free Cash Flow
57.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-308.8% | -444.0%
EBIT
-338.6%
Net
1,410.5% | -786.8%
Free Cash Flow
-540.2%
More
EPS
$0.1
FCF per Share
$0.0
Short interest
0.1%
Employees
23
Rev per Employee
$20.0k
Show more

Is Addex Therapeutics Ltd - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Addex Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

2x Hold
20%
8x Sell
80%

Analyst Opinions

10 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

Hold
20%
Sell
80%

Financial data from Addex Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.79 0.79
54% 54%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.42 2.42
56% 56%
306%
- Research and Development Expense 0.85 0.85
90% 90%
108%
-2.44 -2.44
77% 77%
-309%
- Depreciation and Amortization 0.24 0.24
26% 26%
30%
EBIT (Operating Income) EBIT -2.68 -2.68
75% 75%
-339%
Net Profit 11 11
181% 181%
1,413%

In millions USD.

Don't miss a Thing! We will send you all news about Addex Therapeutics Ltd - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Addex Therapeutics Ltd - ADR Stock News

Neutral
GlobeNewsWire
about one month ago
Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing...
Neutral
GlobeNewsWire
about one month ago
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurode...
Neutral
GlobeNewsWire
about 2 months ago
Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM).
More Addex Therapeutics Ltd - ADR News

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Head office Switzerland
CEO Tim Dyer
Employees 23
Founded 2002
Website www.addextherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today